Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.42 |
| ▸ | TUBB | P07437 | 2/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.42 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.42 |
| ▸ | NQO2 | P16083 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30171329 | 1.00 | CA2 (0.50) | CA2CA4TUBB1TUBB4ATUBB | |
| SCHEMBL9376185 | 0.89 | TUBB1 (0.50) | CA2CA4TUBB1TUBB4ATUBB | |
| SCHEMBL127769 | 0.87 | CA2 (0.55) | CA2CA4TUBB1TUBB4ATUBB | |
| SCHEMBL30701949 | 0.84 | CA9 (0.50) | CA2CA4ACHEKDM4ECYP3A4 | |
| SCHEMBL3674074 | 0.84 | CA9 (0.50) | CA2CA4ACHEKDM4ECYP3A4 | |
| SCHEMBL9109330 | 0.83 | TUBB1 (0.47) | CA2CA4TUBB1TUBB4ATUBB | |
| SCHEMBL1628136 | 0.83 | CA2 (0.54) | CA2CA4TUBB1NQO2ERN1 | |
| SCHEMBL14736781 | 0.82 | TUBB1 (0.40) | CA2CA4TUBB1TUBB4ATUBB | |
| Methane SCHEMBL660326 | 0.82 | CYP3A4 (0.40) | CA2CA4TUBB1TUBB4ATUBB | |
| SCHEMBL147312 | 0.81 | TUBB1 (0.46) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118638107-A | Preparation method of gem-diaryl spiro lactone intermediate | 西南交通大学 | 2024-09-13 | — | — | CN | claimed |
| CN-114773303-B | Preparation method of anticancer drug leader lignan Aglacin B | 西南交通大学 | 2022-11-01 | — | — | CN | claimed |
| CN-108503623-A | A kind of compound and the preparation method and application thereof inhibiting PRMT7 | 四川大学 | 2018-09-07 | — | — | CN | claimed |
| EP-0604409-B1 | OLIGONUCLEOTIDE ANALOGS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2004-07-14 | — | — | EP | claimed |
| US-6355826-B1 | HALOMETHYLATION AN AROMATIC ALDEHYDE COMPOUND AND SALT FORMATION | THE GOODYEAR TIRE & RUBBER COMPANY | 2002-03-12 | — | — | US | claimed |
| EP-0903338-A2 | Synthesis of stable nitrile oxide compounds | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1999-03-24 | — | — | EP | claimed |
| CN-118638107-A | Preparation method of gem-diaryl spiro lactone intermediate | 西南交通大学 | 2024-09-13 | — | — | CN | disclosed |
| US-20230192692-A1 | MACROCYCLIC AND CAGE-LIKE MOLECULE BASED ON BIPHEN[n]ARENE AND DERIVATIVE, SYNTHESIS METHOD AND USE THEREOF | TIANJIN NORMAL UNIVERSITY (CN) | 2023-06-22 | — | — | US | disclosed |
| CN-114773303-B | Preparation method of anticancer drug leader lignan Aglacin B | 西南交通大学 | 2022-11-01 | — | — | CN | disclosed |
| CN-114773303-A | Preparation method of anticancer drug leader lignan Aglacin B | 西南交通大学 | 2022-07-22 | — | — | CN | disclosed |
| CN-106794174-B | Compounds for the treatment of cancer | GTX公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-111253336-A | Compounds for the treatment of cancer | GTX公司 | 2020-06-09 | — | — | CN | disclosed |
| US-10597416-B2 | Complexes | JOHNSON MATTHEY PLC (GB) | 2020-03-24 | — | — | US | disclosed |
| CN-1137895-A | Prevention and curing agent for c attenuation living vaccine | EISAI CO LTD (JP) | 1996-12-18 | — | — | CN | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| US-5104894-A | Ellagic acid analogues | UNIVERSITY OF GUELPH (CA) | 1992-04-14 | — | — | US | disclosed |
| US-3992536-A | SEDATIVES AND MUSCLE RELAXANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-11-16 | — | — | US | disclosed |
| US-3931185-A | SEDATIVES, MUSCLE RELAXANT | BOEHRINGER INGELHEIM GMBH (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597416-B2 | Complexes | C5, C1S, C9 | CA2 137/4885CA4 213/4885TUBB1 4532/4885 |
| US-20230192692-A1 | MACROCYCLIC AND CAGE-LIKE MOLECULE BASED ON BIPHEN[n]ARENE AND DERIVATIVE, SYNTHESIS METHOD AND USE THEREOF | TPMT, NUDT1, PNP | CA2 366/4885CA4 1379/4885TUBB1 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.